Biolinerx Ltd. (BLRX)

Trade BLRX now with
9/3/2019 7:13:24 AM BioLineRx Completes Dose-Escalation Part Of Phase 1/2a Clinical Study For AGI-134 For Treatment Of Solid Tumors
8/6/2019 7:39:49 AM BioLineRx Q2 Net Loss $5.5 Mln Vs. Net Loss Of $4.8 Mln Prior Year
5/14/2019 7:06:09 AM BioLineRx Q1 Operating Loss $5.6 Mln Vs. Operating Loss Of $6.6 Mln Prior Year
5/7/2019 7:10:33 AM BioLineRx Unveils FDA Approval Of IND Application For AGI-134, Novel Immunotherapy Anti-Cancer Vaccine For Solid Tumors
3/27/2019 7:01:52 AM BioLineRx Announces Successful Engraftment Data From Phase 3 GENESIS Trial For BL-8040 In Multiple Myeloma Patients
2/4/2019 5:48:09 PM BioLineRx Begins Public Offering Of ADSs
2/4/2019 7:11:18 AM BioLineRx Receives Orphan Drug Designation From FDA For BL-8040 For Pancreatic Cancer
12/11/2018 7:07:45 AM BioLineRx Announces Initiation Of Triple Combination Arm Of Phase 2a COMBAT/KEYNOTE-202 Study
11/20/2018 7:09:07 AM BioLineRx Announces Receipt Of FDA Biological Product Designation For Novel Cancer Immunotherapy Candidate AGI-134
10/19/2018 7:06:04 AM BioLineRx Presents Top-line Results From Phase 2a COMBAT/KEYNOTE-202 Study In Pancreatic Cancer At ESMO 2018 Congress
8/13/2018 7:08:51 AM BioLineRx Q2 Net Loss $4.8 Mln Vs Net Loss $4.9 Mln Last Year
8/1/2018 7:18:36 AM BioLineRx Begins Phase 1/2a Clinical Study For AGI-134
5/22/2018 7:05:06 AM BioLineRx Q1 Loss Per Share $0.08 Vs Loss $0.06 Last Year
3/26/2018 7:13:48 AM BioLineRx Announces Notice Of Allowance From USPTO For Patent Covering AGI-134 - A Novel Immunotherapy For Solid Tumors
1/17/2018 7:02:34 AM BioLineRx Announces Partial Monotherapy Results From Phase 2a COMBAT Study In Pancreatic Cancer